Edition:
United States

AEterna Zentaris Inc (AEZS.O)

AEZS.O on Consolidated Issue listed on NASDAQ Capital Market

3.45USD
5 Dec 2016
Change (% chg)

-- (--)
Prev Close
$3.45
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
284,214
52-wk High
$7.97
52-wk Low
$2.60

AEZS.O

Chart for AEZS.O

About

Aeterna Zentaris Inc. is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The... (more)

Overall

Beta: 1.74
Market Cap(Mil.): $40.29
Shares Outstanding(Mil.): 11.67
Dividend: --
Yield (%): --

Financials

  AEZS.O Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -3.14 -- --
ROI: -94.77 -1.09 14.95
ROE: -332.57 -2.39 16.29

BRIEF-Aeterna zentaris Q3 loss per share $0.61

* Aeterna Zentaris - believe have funds necessary to complete two pivotal clinical trials, to report top-line results on both, to file a nda for macrilen in first half of 2017

Nov 08 2016

BRIEF-Aeterna Zentaris says announces $7.6 mln registered direct offering

* Aeterna zentaris announces us$7,560,000 registered direct offering of common shares and warrants

Oct 27 2016

BRIEF-Aeterna Zentaris completes patient recruitment for confirmatory phase 3 trial of Macrilen

* Aeterna Zentaris completes patient recruitment for confirmatory phase 3 trial of Macrilen

Oct 26 2016

BRIEF-Aeterna and Specialised Therapeutics Asia sign exclusive license agreement

* Aeterna Zentaris and Specialised Therapeutics Asia sign exclusive license agreement for the potential marketing of Zoptrex(TM) in Australia and New Zealand

Oct 12 2016

BRIEF-AEterna Zentaris announces expiration of remaining Series B warrants

* AEterna Zentaris announces expiration of remaining Series B warrants

Sep 14 2016

BRIEF-Aeterna Zentaris reports Q2 loss per share $0.71

* Aeterna Zentaris reports second quarter 2016 financial and operating results

Aug 09 2016

BRIEF-Aeterna and Rafa Laboratories sign license agreement for Zoptrex in Israel

* Aeterna Zentaris and Rafa Laboratories sign exclusive license agreement for Zoptrex in Israel

Aug 01 2016

BRIEF-Aeterna Zentaris, Orient Europharma sign license agreement for Zoptrex

* Aeterna Zentaris and Orient Europharma Co Ltd sign exclusive license agreement for Zoptrex in Taiwan and Southeast Asia

Jul 01 2016

BRIEF-Aeterna zentaris to file a NDA for zoptrex in first half of 2017

* Aeterna Zentaris reconfirms commitment to LHRH-receptor targeting zoptrex during 2016 ASCO annual meeting

Jun 06 2016

Earnings vs. Estimates